๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Clinical trials in neuromuscular disease

โœ Scribed by Dr. Theodore L. Munsat

Publisher
John Wiley and Sons
Year
1990
Tongue
English
Weight
290 KB
Volume
13
Category
Article
ISSN
0148-639X

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Therapeutic trials in neuromuscular dise
Therapeutic trials in neuromuscular diseases
โœ Walter G. Bradley ๐Ÿ“‚ Article ๐Ÿ“… 1981 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 76 KB

T h e treatment of a disease may spring from an understanding of the underlying etiology of that disease, or it may arise less directly. For instance, the use of L-dopa in the treatment of Parkinson's disease arose from the finding of deficient dopamine levels in the brains o f Parkinsonian patients

Neuromuscular disease: Evidence and anal
Neuromuscular disease: Evidence and analysis in clinical neurology
โœ S. Claiborne Johnston ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 38 KB

A lack of high-quality evidence often forces us to rely on other sources of information, such as clinical experience, expert opinion, and extrapolation from pathophysiology, to make decisions about patient management. After years of practice, we began to accept these "truths" from nonempirical evide

Attitudes in clinical trials
Attitudes in clinical trials
โœ Peter Armitage ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 74 KB ๐Ÿ‘ 2 views

Two important papers by Schwartz and Lellouch have drawn distinctions between explanatory and pragmatic attitudes to clinical trials, and between individual and collective ethics. The pragmatic approach accords with the widespread use of 'intention-to-treat' analyses, but recent research has started